Neoadjuvant Chemotherapy Therapy News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Many TNBC Patients Unnecessarily Opt for Mastectomy
The use of neoadjuvant chemotherapy increases eligibility for breast-conserving therapy in triple-negative breast cancer patients, yet many still opt for mastectomy. (Source: CancerNetwork)
Source: CancerNetwork - June 16, 2017 Category: Cancer & Oncology Authors: Mark Fuerst Tags: Breast Cancer News Triple-Negative Breast Cancer Source Type: news

COUNTERPOINT: Primary Debulking Surgery vs Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer
In a Significant Percentage of Patients, Neoadjuvant Therapy Yields Equivalent Survival, With Better Quality of Life and Lower Costs (Source: CancerNetwork)
Source: CancerNetwork - June 15, 2017 Category: Cancer & Oncology Authors: Anna Fagotti, MD, PhD Giovanni Scambia, MD Tags: Gynecologic Cancers Oncology Journal Ovarian Cancer Source Type: news

POINT: Primary Debulking Surgery vs Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer
Cytoreductive Surgery Is the Best Way to Affect Survival Outcomes (Source: CancerNetwork)
Source: CancerNetwork - June 15, 2017 Category: Cancer & Oncology Source Type: news

Adjuvant Capecitabine Improves Survival in Residual Invasive Breast Cancer
Patients with HER2-negative breast cancer with residual invasive disease following neoadjuvant chemotherapy benefit from adjuvant treatment with capecitabine. (Source: CancerNetwork)
Source: CancerNetwork - June 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news

Neoadjuvant Chemotherapy Improves Clinical Response in Breast Cancer
For premenopausal breast cancer patients, 24 weeks of neoadjuvant chemotherapy may yield a better clinical response than endocrine therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2017 Category: Cancer & Oncology Authors: Mark Fuerst Tags: Conferences/ASCO Breast Cancer News Source Type: news

Bevacizumab Does Not Improve Response, Survival in Ovarian Cancer
Adding bevacizumab to neoadjuvant chemotherapy did not improve complete macroscopic response rate or progression-free survival in women with ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Ovarian Cancer News Source Type: news

Treatment of Low-Lying Early Rectal Cancer
This video examines the treatment of patients with low-lying rectal cancer and explores options such as neoadjuvant chemoradiotherapy, which could improve the efficacy of surgery. (Source: CancerNetwork)
Source: CancerNetwork - May 25, 2017 Category: Cancer & Oncology Authors: Julio Garcia-Aguilar, MD, PhD Tags: Videos Gastrointestinal Cancers Source Type: news

Watch-and-Wait for Some Rectal Cancer Patients After Chemoradiation Watch-and-Wait for Some Rectal Cancer Patients After Chemoradiation
Among patients with locally advanced rectal cancer who have a clinical complete response to neoadjuvant chemoradiation, most will not experience tumor regrowth and may avoid radical surgery when a wait-and-watch approach is used, new research suggests.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 22, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
Dateline City: KENILWORTH, N.J. Now Approved for First-Line Treatment in Patients Ineligible for Cisplatin-Containing Chemotherapy and Second-Line Treatment in Patients Who Have Disease Progression During or Following Platinum-Containing Chemotherapy or Within 12 Months of Neoadjuvant or Adjuvant Treatment with Platinum-Containing Chemotherapy KEYTRUDA is the Only Anti-PD-1 Therapy to Demonstrate Superior Overall Survival Versus Chemotherapy in Patients With Advanced Urothelial Carcinoma Post-Platinum FailureKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the Unit...
Source: Merck.com - Product News - May 18, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK NYSE:MRK Source Type: news

New VTE Often Occurs During Chemo in Ovarian Cancer
Most cases of venous thromboembolism occurred during neoadjuvant or adjuvant chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 11, 2017 Category: Cancer & Oncology Tags: Cardiology, Gynecology, Nursing, Oncology, Surgery, Journal, Source Type: news

Pathologic complete response to neoadjuvant therapy in certain breast cancer patients predicts low risk for local metastases
(University of Texas M. D. Anderson Cancer Center) Select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy may be able to avoid follow-up breast and lymph node, or axillary, surgery, according to new findings from researchers at The University of Texas MD Anderson Cancer Center. The study, published today in JAMA Surgery, identifies the exceptional responders who are at lowest risk for local metastases and thereby are candidates for less invasive treatment options. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 19, 2017 Category: Cancer & Oncology Source Type: news

Residual Disease Prognostic for Breast Cancer Survival (CME/CE)
(MedPage Today) -- Index may predict success of neoadjuvant chemotherapy (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - April 6, 2017 Category: OBGYN Source Type: news

A New Trend in Pancreatic Cancer Treatment A New Trend in Pancreatic Cancer Treatment
Neoadjuvant chemotherapy is now being used in various centers for select patients. And clinical trials are pushing the presurgery chemo envelope in patients who are ' borderline ' candidates for surgery. Here ' s why.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 30, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Novel Calculator Guides Treatment Choice in Esophageal Cancer
A novel calculator can more easily identify which esophageal adenocarcinoma patients derive an overall survival benefit from neoadjuvant chemoradiation to help guide treatment choices. (Source: CancerNetwork)
Source: CancerNetwork - March 23, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Esophageal Cancer Gastrointestinal Cancer News Source Type: news